Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
For researchers running this stack regularly, the blended format is the simpler option
Diabetologia, 67 (7), 12061222
The published SURMOUNT-1 data in adults without diabetes over 72 weeks, per Eli Lilly's disclosed trial information: 5mg dose: average weight loss of 15.0% of body weight (approximately 34 lbs) 10mg dose: average weight loss of 19.5% of body weight (approximately 44 lbs) 15mg dose: average weight loss of 20.9% of body weight (approximately 48 lbs) Placebo: average weight loss of 3.1% (approximately 7 lbs) Average starting weights ranged from 226.8 to 233.3 lbs across dose groups
It is a triple agonist, targeting GLP-1, GIP, and glucagon receptors, three separate hormonal pathways working simultaneously to suppress appetite, accelerate fat metabolism, and improve insulin sensitivity
Prevents scarring
/assets/images/provider/photos/2775905.jpeg)
